Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependence Blue Cross Medicare Part B Step Thera…
    Ask Trek AI about this page
    CurrentIndependence Blue CrossPolicy N/A

    Medicare Part B drugs subject to step therapy

    Customize your policy alerts

    Sign up for all independence_blue_cross policy alerts

    Know when independence_blue_cross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists Medicare Part B drugs subject to step therapy at Independence Blue Cross, identifying preferred and non-preferred products by drug category and describing the plan's step therapy approach for Medicare members.

    Policy Summary
    PayerIndependence Blue Cross
    PolicyMedicare Part B drugs subject to step therapy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionProviders must have members try the plan-designated preferred product(s) for the drug category before IBX will cover a non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplecategories with step therapy lists
    preferred vs non-preferredpreference specified
    subject to changelist not exhaustive
    IBX Help Teamcontact info

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage criteria — step therapy conditions

    Step therapy coverage condition

    Covered when ALL of the following are met

    Step therapy requirement: Member has tried and failed or is intolerant to the plan-designated preferred product for the specific drug category prior to coverage of a non-preferred productN/A

    Preferred products and non-preferred products are listed by drug category in this policy (e.g., cancer agents, colony-stimulating factors, IV iron, IVIG, ophthalmologic VEGF agents, denosumab, etc.). See the category lists for specific product mappings.

    The lists of Medicare Part B drugs subject to step therapy in this document are not exhaustive. For a complete listing or for clarification about whether a specific drug is subject to step therapy, providers and members should contact the IBX Help Team at 1-800-ASK-BLUE (available 8 a.m. to 8 p.m., Monday–Friday) or visit ibx.com/medicare. Coverage rules and the preferred/non‑preferred drug lists are subject to change; when in doubt, confirm current requirements with IBX prior to initiating or billing for non-preferred products.

    What providers need to do

    Prior Authorization

    Step therapy requirement — try preferred product first

    Independence Blue Cross may require members to try a plan-designated preferred product before IBX will cover a non-preferred Medicare Part B drug (step therapy).

    Step Therapy

    Step therapy process — preferred-product trial required

    The plan designates certain drugs as preferred products that members must try before IBX will cover non-preferred products; requirements and the specific preferred-product lists are available in the medical policies and the list is subject to change.

    • Preferred-product requirements are available in IBX medical policies.
    • The list of preferred and non-preferred products is subject to change.
    Documentation Required

    Help/contact for coverage details

    For a complete listing of preferred and non-preferred Medicare Part B drugs or for clarification, providers or members should call the IBX Help Team or visit ibx.com/medicare.

    • Call 1-800-ASK-BLUE, 8 a.m. to 8 p.m., Monday–Friday.
    • Visit ibx.com/medicare for listings and details.
    Denial Risk

    Denial risk — non-preferred drugs without prior preferred trial

    Coverage for a non-preferred product may be denied unless the member has first tried a plan-designated preferred product in accordance with the step therapy process.

    Key definitions

    Step therapy (definition)
    DefinitionA utilization management process where the health plan designates preferred products that members must try before the plan will cover a non-preferred product.
    PurposeUsed when multiple treatment options have similar clinical results to encourage use of preferred (typically clinically appropriate and cost-effective) products first.
    Provider requirementMembers must try a plan-designated preferred product prior to coverage of a non-preferred product; requirements for preferred products are available in the medical policies.
    Effect on coverageIBX may deny coverage for non-preferred products unless the preferred-product trial requirement is met.
    Scope and updatesPreferred-product requirements and the list of affected drugs are available in IBX medical policies and the list is subject to change.

    Background and rationale

    Step therapy is used when multiple treatment options demonstrate similar clinical outcomes. Under this utilization management approach, the plan designates preferred products within a drug category that members are required to try before the plan will cover a non-preferred product. The intent is to standardize initial therapy around preferred agents; if a member fails to respond to or is intolerant of a preferred agent (or has another clinically acceptable reason), the plan may then consider coverage of an alternative non-preferred product.

    Initial therapy — preferred product trial

    Initial therapy step — Preferred-product trial

    Preferred-product trial

    Initial step: Member is required to try the plan-designated preferred product(s) for the drug category before the plan will cover a non-preferred product.N/A

    Preferred products by category are listed in this policy (see categories such as IV iron Level 1, oncology agents, CSFs, IVIG, ophthalmologic VEGF agents, etc.).

    Step therapy drug lists and required trials

    Drug categoryPreferred product(s)Non-preferred product(s)Coverage requirement
    CancerEligard®, Camcevi®, Lupron depot®; Alymsys®, Avastin®, Avzivi®, Herceptin®, Hercessi®, Herceptin Hylecta™, Herzuma®; Riabni™, Ruxience®, Truxima™Camcevi®, Trazimera™ and other listed non-preferred oncology products per policyMember must try designated preferred product(s) for the cancer category before IBX will cover a non-preferred product.
    Colony-stimulating factors (long-acting)Fulphila™, Neulasta®Fylnetra™, Nyvepria®, Rolvedon®, Stimufend®, Udenyca®, Ziextenzo™Member must try designated preferred long-acting CSF prior to coverage of non-preferred long-acting CSF.
    Colony-stimulating factors (short-acting)Nivestym®, Zarxio®Neupogen®, Granix®, Releuko®Member must try designated preferred short-acting CSF prior to coverage of non-preferred short-acting CSF.
    Denosumab productsJubbonti®, Stoboclo®, Osenvelt®, Wyost®Aukelso™, Bildyos®, Bilprevda®, Bomyntra®, Bosaya™, Connexence®, Enoby®, Ospomyv®, Prolia®, Xbryk®, Xgeva®, Xtrenbo®Member must try designated preferred denosumab product(s) before denosumab-branded non-preferred products will be covered.
    Eculizumab productsEpysqli®Soliris®, Bkemv®Member must try Epysqli® (preferred) before IBX will cover non-preferred eculizumab products.
    Hyaluronate acid productsMonovisc®, Orthovisc®, Synvisc®, Synvisc-One®Durolane®, Euflexxa™, Gel-One®, Gelsyn3™, GenVisc-850®, Hyalgan®, Hymovis®, Supartz®, Synojoynt™, Triluron™, TriVisc™, VISCO-3®Member must try a plan-designated preferred hyaluronate product before coverage of non-preferred products in this class.
    Infliximab productsAvsola™, Inflectra®, Infliximab (unbranded), Ixifi®, Remicade®, Renflexis®(No separate non-preferred infliximab products listed; policy identifies preferred infliximab products)Member must try a preferred infliximab product before IBX will cover a non-preferred infliximab product.
    IV IronPreferred products (Level 1): All generic IV Iron (Feraheme®, Ferrlecit®, INFeD®, Venofer®)Non-preferred products (Level 2): Injectafer®, Monoferric®Member must try Level 1 preferred IV iron products before coverage of Level 2 non-preferred IV iron products.
    Intravenous Immune Globulin (IVIG)Bivigam®, Cutaquig®, Cuvitru®, Flebogamma®, Flebogamma DIF®, Gamastan S/D®, Gammagard Liquid®, Gammagard S/D®, Gammaked®, Gammaplex®, Gamunex-C®, Hizentra®, HyQvia®, Octagam®, Privigen®, Xembify®, Yimmugo®Alyglo®, Asceniv®, Panzyga®Member must try designated preferred IVIG product(s) before IBX will cover non-preferred IVIG products.
    Myasthenia Gravis agentsVyvgart®, Rystiggo®Imaavy®, Ultomiris®, Epysqli®, Soliris®, Bkemv™Member must try Vyvgart® or Rystiggo® (preferred) before coverage of non-preferred MG agents.
    Ophthalmologic VEGF agentsPreferred products (Level 1): Alymsys®, Avastin®, Avzivi®, Mvasi®, Vegzelma®, Zirabev®Non-preferred products (Level 2 and 3): Byooviz™, Cimerli®, Lucentis®Member must try a Level 1 preferred ophthalmologic VEGF product before IBX will cover Level 2/3 non-preferred ophthalmologic VEGF products.
    Ustekinumab productsYesintek™Imuldosa™, Otulfi®, Pyzchiva®, Selarsdi™, Starjezma®, Stelara®, Steqeyma®, Wezlana™Member must try Yesintek™ (preferred) before coverage of non-preferred ustekinumab products.
    Tocilizumab productsTyenne®Actemra®, Avtozma®, Tofidence™Member must try Tyenne® (preferred) before IBX will cover non-preferred tocilizumab products.

    Biosimilar guidance

    Billing Rule

    Infliximab originator (Remicade®) listed as preferred

    Remicade® (the infliximab originator) is listed among IBX’s preferred infliximab products.

    • Preferred infliximab products include Avsola™, Inflectra®, Infliximab (unbranded), Ixifi®, Remicade®, Renflexis®
    Policy Summary
    PayerIndependence Blue Cross
    PolicyMedicare Part B drugs subject to step therapy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionProviders must have members try the plan-designated preferred product(s) for the drug category before IBX will cover a non-preferred product.
    SourceLink
    On This Page
    Coverage criteria — step therapy conditionsWhat providers need to doKey definitionsBackground and rationaleInitial therapy — preferred product trialStep therapy drug lists and required trialsBiosimilar guidance